hat
Jounal antineoplastik ajan ak MMAE dwòg antimitotik parèt tankou molekil chajtotoksik nan omwen sèz ADC ki te pwogrese nan tras klinik21. Pami sa yo se ADC Brentuximab vedotin a ki itilize nan tretman an nan repa ka nan lymphoma Hodgkin a ak anaplastik gwo selil lenfoma24. MMAE konpoze de senk peptide résidus e li te rapòte pou egziste nan solisyon kòm yon melanj de de konformatè akòz yon wotasyon pasyèl anpeche alantou bond la amid dolaproine-dollarisoleuine. Estrikti chimik cis / trans-isomèr yo, enfòmasyon sou résidans asid amine ak nimero ki pral itilize nan diskisyon an rezime nan imaj malye:
eng
The antineoplastic agent and antimitotic drug MMAE appears as the cytotoxic payload molecule in at least sixteen ADCs which have progressed to clinical trials21. Among these is the ADC Brentuximab vedotin which is utilised in the treatment of relapsed cases of Hodgkin’s lymphoma and anaplastic large cell lymphoma24. MMAE is composed of five peptide residues and has been reported to exist in solution as a mixture of two conformers due to a partially hindered rotation around the dolaproine-dolaisoleuine amide bond. The chemical structure of the cis/trans-isomers, information on the amino acid residues and the numbering that will be utilised in the discussion is summarised in bellow image: